TERT promoter hotspot mutations are recurrent in myxoid liposarcomas but rare in other soft tissue sarcoma entities
about
Cancer-Specific Telomerase Reverse Transcriptase (TERT) Promoter Mutations: Biological and Clinical ImplicationsTranscription Regulation of the Human Telomerase Reverse Transcriptase (hTERT) GeneRoles of telomeres and telomerase in cancer, and advances in telomerase-targeted therapiesTERT promoter mutations are rare in bone and soft tissue sarcomas of Japanese patientsPleomorphic Liposarcoma Arising in a Lipoleiomyosarcoma of the Uterus: Report of a Case With Genetic Profiling by a Next Generation Sequencing Panel.Arginine deiminase expressed in vivo, driven by human telomerase reverse transcriptase promoter, displays high hepatoma targeting and oncolytic efficiency.Next generation sequencing in synovial sarcoma reveals novel gene mutations.The molecular landscape of extraskeletal osteosarcoma: A clinicopathological and molecular biomarker study.Establishment and characterization of a new human myxoid liposarcoma cell line (DL-221) with the FUS-DDIT3 translocation.Telomerase promoter mutations in cancer: an emerging molecular biomarker?Risk assessment in solitary fibrous tumors: validation and refinement of a risk stratification model.Telomere maintenance in soft tissue sarcomasUnderstanding TERT Promoter Mutations: A Common Path to Immortality.Alternative lengthening of telomeres and loss of ATRX are frequent events in pleomorphic and dedifferentiated liposarcomas.TERT promoter mutations and BRAF mutations are rare in sporadic, and TERT promoter mutations are absent in NF1-related malignant peripheral nerve sheath tumors.Diagnosis and treatment of ALT tumors: is Trabectedin a new therapeutic option?TERT promoter mutations and prognosis in solitary fibrous tumor.Presence of TERT Promoter Mutations is a Secondary Event and Associates with Elongated Telomere Length in Myxoid Liposarcomas.Comprehensive screening of alternative lengthening of telomeres phenotype and loss of ATRX expression in sarcomas.Differential nuclear ATRX expression in sarcomas.Radiotherapy plus concomitant temozolomide in primary gliosarcoma.Detection of Aberrant TERT Promoter Methylation by Combined Bisulfite Restriction Enzyme Analysis for Cancer Diagnosis.A review of soft-tissue sarcomas: translation of biological advances into treatment measures.Telomere Maintenance Mechanisms in Cancer.Different patterns of clonal evolution among different sarcoma subtypes followed for up to 25 years
P2860
Q54581310-A14FFB11-527F-4BAC-BB30-E9A2C6FE96EEQ54582361-D5898BF8-5C21-4F00-9DF4-672E75C630F0Q54602862-1BB84BB2-CC35-440A-9A6B-2DECC519BC3BQ54813754-D8819529-AF2E-461F-B96B-FBBE6D9F1206Q54835233-96F6CE43-47A5-43C6-B069-0F3230291422Q54835267-E8601AE2-F23C-4172-BFD4-D863C19D37ACQ54896293-76EC3960-8DFC-4485-83FC-2DB4E78E27F5Q54902640-304BAD89-2F27-4039-BD44-7AE6F1EBDE01Q54955754-4D8B152D-167D-454D-B7E6-361B2D4AFD6DQ54970640-33EB0C57-2E4B-4683-AC32-2778E92845E9Q54971215-DF9D2DAC-9DBD-44E2-B687-8A2CBE205F1DQ54971281-594217CF-1F5B-4C04-8316-5802C45EAF88Q54971479-9A89566A-FF78-473C-9EB3-2574C8B8F152Q54971558-9C9732A7-2E4B-48A9-841E-F76E5D76DDD1Q54971617-895C4F05-A3FE-483E-B1C0-DCEC45AA6E31Q5636047-38F91315-BF14-45CD-9122-C68072CD33BB
P1343
Q26738705-3E6D1B23-6B71-472B-8085-FE48BBACC11AQ26739925-927B63DE-C7BF-4A7C-A485-AA5562271A19Q26744271-B6B7F48E-920A-4956-8F4D-43D7A25FC80BQ33429964-857197C2-7BAF-41D4-839C-8ACB1F0A7EB0Q33880273-CDB9D3E1-99E4-4B9E-BE3F-CA0CA8789C08Q33914097-A3D696D5-560E-4CFA-8581-6EF9F7CA76D8Q36544186-5B7B0237-5C29-49EF-9506-BAFA8D93E144Q36873828-8C76CCFD-0BDB-459D-A06E-6029DAD6F6A6Q37136357-389E99AD-098B-458A-B42A-8180852D3BF5Q38232447-6A65F51E-06A8-4AFB-9DF3-A10C02BBA4E3Q38668396-AEDE6FD9-0B29-46AD-A595-D558D95EA652Q38759188-97487267-6A71-4532-A733-BD435C0AFD34Q38760235-52618816-DF2C-46FF-BB46-356207FF98A8Q41710355-92B59D65-3A66-4EFF-8386-BA4D72EB1574Q42205608-FA6521B8-7AF8-46A9-A9F5-942211875C13Q47095909-62820747-81E0-4FC8-B1AF-D33F23AF3841Q47147053-1A2D23E0-52D4-493F-8F63-A5ED054256CAQ49803880-5477C95D-4D01-4C43-B1A6-7CC03AEEF500Q50561703-82FDD865-B65A-486A-BCFC-5BBCC51F65DFQ50572191-9C37647C-0BF9-40DD-80D7-5291A5238170Q52143329-B879A920-A716-4DF4-87D1-D52FB42207AAQ55003880-BB0F077C-A471-4079-986B-BC8B3E3EA587Q55265062-C19BDBA9-F893-4483-82AF-107A1DE68890Q55443450-3D1D180E-B9CC-4107-8E2A-384699D2FB4AQ58756420-F35C41B9-BB26-4035-9C7C-84B955713E50
P2860
TERT promoter hotspot mutations are recurrent in myxoid liposarcomas but rare in other soft tissue sarcoma entities
description
2014 nî lūn-bûn
@nan
2014 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
TERT promoter hotspot mutation ...... r soft tissue sarcoma entities
@ast
TERT promoter hotspot mutation ...... r soft tissue sarcoma entities
@en
type
label
TERT promoter hotspot mutation ...... r soft tissue sarcoma entities
@ast
TERT promoter hotspot mutation ...... r soft tissue sarcoma entities
@en
prefLabel
TERT promoter hotspot mutation ...... r soft tissue sarcoma entities
@ast
TERT promoter hotspot mutation ...... r soft tissue sarcoma entities
@en
P2093
P2860
P4510
P356
P1476
TERT promoter hotspot mutation ...... r soft tissue sarcoma entities
@en
P2093
Burkhard Lehner
Christian Koelsche
Eva Wardelmann
Gerlinde Egerer
Gunhild Mechtersheimer
Ingo Alldinger
Marcus Renner
Nina Waldburger
Peter Schirmacher
Regine Brandt
P2860
P2888
P356
10.1186/1756-9966-33-33
P577
2014-04-11T00:00:00Z
P5875
P6179
1015633596